MedTrace Logo

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

NCT02776215 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-03-21

No results posted yet for this study

Summary

Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents.

Conditions

Interventions

DRUG

tasimelteon

Melatonin receptor agonist

Sponsors & Collaborators

Principal Investigators

  • Vanda Pharmaceuticals · Sponsor GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-04
Primary Completion
2017-12-20
Completion
2017-12-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02776215 on ClinicalTrials.gov